Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

September 22, 2023

Myth Busting: Master Protocol Edition

Interest and appetite for master protocols is growing as sponsors consider opportunities in various therapeutic areas...

Read article

December 29, 2022

Top Perspectives Articles of 2022

Perspectives on Enquiry and Evidence explores a wide variety of topics within clinical trial design and data science in...

Read article

December 14, 2022

Accrual When Starting a Platform Trial vs. in a Stand-Alone Trial

When evaluating the efficacy of a candidate investigational therapy, a standard clinical trial paradigm is to conduct a...

Read article

October 5, 2022

Platform Trials, Can they Benefit Animal Studies?

Master protocols and platform clinical trials have become an innovative and efficient approach to testing multiple...

Read article

August 30, 2022

Understanding the Economic Benefits of Platform Trials

Many thanks to Kyle Wathen and Behnam Sharif for their input on this post.

Read article

July 12, 2022

Strategies for Selecting New Indications for a Platform Trial

Thanks to Dr. Kyle Wathen for comments on this blog. The increasing use of platform trials for the testing of a wide...

Read article

June 29, 2022

Platform Trials, Master Protocols, and Challenges in Execution

How can we build an efficient statistical protocol for a clinical trial, if we do not know the therapies that will be...

Read article

January 21, 2022

How to Use and Interpret the Results of a Platform Trial

For our first Winter Weekend Read, Cytel presents How to Use and Interpret the Results of a Platform Trial, a JAMA...

Read article

October 29, 2021

Designing Platform Trials

A platform trial, a type of Master Protocol, is an experimental infrastructure to evaluate multiple treatments and/or...

Read article

October 15, 2021

Applications of Master Protocols in a Global Health Context

Almost 3000 registered trials were performed in COVID-19 and a majority of them have been small and likely...

Read article

May 21, 2021

Use of Bayesian Analysis in Platform Trials: Webinar by Dr. Kyle Wathen

Most of us are familiar with the concept of platform clinical trials as they have gained popularity in the recent...

Read article

December 2, 2020

Program and Portfolio Optimization: A New Paradigm

Significant advances have been made to enhance the efficiency of clinical trial designs. However, the traditional...

Read article

November 10, 2020

Key Design Considerations for Platform Trials

Platform trials are a new type of clinical trials where multiple interventions can be evaluated simultaneously against...

Read article

October 9, 2020

Cyrus Mehta on Increasing the Power of Platform Trials

Even before the era of COVID-19, significant attention was channeled to the overwhelming potential of adaptive MAMS...

Read article

September 30, 2020

A Virtual Event Brought to you by Cytel and Novartis on Innovations

Today, there is a need for advanced quantitative techniques to combine all available information for better decision...

Read article

September 28, 2020

Advantages of platform designs for investigating COVID-19 therapies

Cytel has recently designed and implemented the TOGETHER Trials, funded by the Bill & Melinda Gates Foundation to...

Read article

September 21, 2020

Novel Adaptive Platform Trial for COVID-19 Therapies

Cytel has designed and implemented a novel adaptive platform trial for early stage COVID-19. The severity of the...

Read article

June 24, 2020

Webinar - Practical Model-based Approaches for Phase I Oncology Trials

Last week, Cytel conducted its third webinar in the new introductory webinar series on Complex Innovative Trial...

Read article

June 15, 2020

Significance of Bayesian Model-Based Approaches in Oncology Trials: An Interview with Dr. Satrajit Roychoudhury

Cytel conducted a webinar with Dr. Satrajit Roychoudhury, Senior Director, Statistical Research and Data Science...

Read article

June 11, 2020

Adaptive Bayesian Methods: The Secret Weapon in COVID-19 Vaccine Development

A recent Cytel panel led by Vice President of Strategic Consulting Natalia Muhlemann evaluated the role that Bayesian...

Read article

June 1, 2020

Webinar Replay: Innovative Drug Development at a Glance

In a recent interview with Cytel, Zoran Antonijevic, longstanding chair and leader of the DIA Adaptive Design...

Read article

May 18, 2020

Interview with Zoran Antonijevic on Adaptive Design Methods

In this blog, we speak with Zoran Antonijevic, longstanding chair and leader of the DIA Adaptive Design Scientific...

Read article

May 1, 2020

Weekly Insights from Cytel's COVID-19 Trial Tracker

There are currently 665 trials registered at Cytel’s COVID-19 Trial Tracker, a jump of over 100 trials in the past two...

Read article

April 14, 2020

Early Insights from Cytel’s New COVID-19 Trial Tracker

Last week Cytel launched a COVID-19 Trial Tracker, an Open Access tool to track the global response to the coronavirus...

Read article

March 12, 2020

Interview with Jay Park: The present and future of Master Protocols

In September 2018, the FDA provided a draft guidance on master protocols reflecting an increased interest in these...

Read article